The question remains. Do we know if the B-OM patients in the trial benefited from an abbreviated duration of SOM once it set in, or did the B group suffer for the same length of time following the delayed onset? I understand all of the positive trial results, which I agree will no doubt lead to a lucrative deal for us. Having said that, I think that my question will be on the minds of many other longs until we have a definitive answer. Certainly someone has the answer, and it would be good to know. GO IPIX IN 2018!!
Market Data 
Markets 
AI
